Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Oxacillinase (OXA)-producing Acinetobacter baumannii in Brazil: clinical and environmental impact and therapeutic options

Full text
Author(s):
Micheli Medeiros [1] ; Nilton Lincopan [2]
Total Authors: 2
Affiliation:
[1] Universidade de São Paulo. Faculty of Pharmaceutical Sciences. Clinical Analysis Department
[2] USP. Faculty of Pharmaceutical Sciences. Clinical Analysis Department
Total Affiliations: 2
Document type: Journal article
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial; v. 49, n. 6, p. 391-405, 2013-12-00.
Abstract

Following a worldwide trend, infections caused by MDR OXA-type (Ambler class D) carbapenemase-producing Acinetobacter baumannii are currently regarded as a clinical and epidemiological emergency in Brazil. OXA-producing A. baumannii strains have been identified in the states of Alagoas, Amazonas, Bahia, Distrito Federal, Espírito Santo, Goiás, Mato Grosso, Mato Grosso do Sul, Minas Gerais, Paraná, Pernambuco, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul, Santa Catarina and São Paulo. In some settings, the presence of OXA-23- and/or OXA-143 -producing A. baumannii (so far restricted to Brazil) has been endemic and A. baumannii strains carrying blaOXA-23 genes have been detected in hospital wastewater effluents, hence a potential risk to the community and the environment. Although molecular typing by multilocus sequence typing (MLST - Bartual scheme, University of Oxford, http://pubmlst.org/abaumannii/) has revealed the international spread of a clonal complex (CC) denominated CC92, in Brazil most OXA-23-producing A. baumannii belong to CC113, CC109 or CC104 clonal complexes. Finally, from a clinical point of view, the main problem of A. baumannii infections is the limited use of antibacterial agents with in vitro activity, often restricted to ampicillin/sulbactam, polymyxin B and/or colistin (polymyxin E). (AU)

FAPESP's process: 11/04025-2 - In vitro and in vivo evaluation of synergistic effects of combinations of antibacterials for the treatment of infections due to KPC and OXA-type carbapenemase-producing multidrug-resistant gram-negative bacteria endemic in Brazil
Grantee:Micheli Medeiros
Support Opportunities: Scholarships in Brazil - Master